Controlling bleeds, whenever they happen. NovoSeven® RT is proven effective in controlling bleeding episodes, and preventing bleeds during surgery, in adults and children across 4 indicated disorders.
NovoSeven® RT:
Experience where it matters.
Here’s why NovoSeven® RT may be right for you.
Here’s why it may be right for you:
Room temperature stable and travel ready. NovoSeven® RT requires no refrigeration. After mixing, you may keep it in the vial for up to 3 hours.a
aNovoSeven® RT should be stored between 36°F and 77°F.
For complete storage instructions, please see the Prescribing Information.
Speed when it’s needed. Fast to mix with our MixPro® device, fast to infuse, and fast to control bleeds.b
bAdminister as a slow bolus injection over 2-5 minutes, depending on the dose administered.
NovoSeven® RT is committed to your experience. More than 30 years of research and long-term clinical experience.c
cCompassionate use, also known as expanded access, began enrolling in 1988; FDA approval received in 1999.
NovoSeven® RT: Experience where it matters.
Here’s why it may be right for you:
Controlling bleeds, whenever they happen. NovoSeven® RT is proven effective in controlling bleeding episodes, and preventing bleeds during surgery, in adults and children across 4 indicated disorders.
Room temperature stable and travel ready. NovoSeven® RT requires no refrigeration. After mixing, you may keep it in the vial for up to 3 hours.a
aNovoSeven® RT should be stored between 36°F and 77°F.
For complete storage instructions, please see the Prescribing Information.
Speed when it’s needed. Fast to mix with our MixPro® device, fast to infuse, and fast to control bleeds.b
bAdminister as a slow bolus injection over 2-5 minutes, depending on the dose administered.
NovoSeven® RT is committed to your experience. More than 30 years of research and long-term clinical experience.c
cCompassionate use, also known as expanded access, began enrolling in 1988; FDA approval received in 1999.
Committed to leadership in research and treatment.
NovoSeven® RT has a long history of helping people control their bleeds. Over 30 years of research is behind this treatment,d and today, we continue our commitment to finding new ways to help people with bleeding disorders.
dCompassionate use, also known as expanded access, began enrolling in 1988; FDA approval received in 1999.

Clockwise from top right: Taylor, Jack, Bob, Henry, Sid, Justin, Chase, and Kali. Taylor has factor VII deficiency; Jack, Bob, Sid, Justin, and Chase have hemophilia A with inhibitors; Henry has acquired hemophilia; Kali has Glanzmann’s thrombasthenia with resistance to platelets.
![Syringe and vials of NovoSeven® RT (Coagulation Factor VIIa [Recombinant])](/content/dam/novonordisk/novoseven/cta/CTA-safety-profile.png)
Considering NovoSeven® RT?
When it comes to on-demand bleed treatment, you have a choice. Find out how NovoSeven® RT can fit into your lifestyle—and may be the right choice for you.